ReviewFrontiers in dental medicine2025
Gingival crevicular fluid as a functionalized point of care for the early detection of dementia or the asymptomatic phase of neurodegeneration.
Review in Frontiers in dental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing evidence links chronic systemic inflammation, particularly from periodontitis, to neurodegenerative processes, which have been reported to share common pathways. Early detection of neurodegenerative diseases such as Alzheimer's disease is crucial, given that underlying neuropathological processes evolve silently for decades before diagnosis. The gingival crevicular fluid (GCF), a serum-derived exudate from the gingival sulcus, mirrors both local periodontal inflammation and systemic conditions. Its molecular composition-rich in cytokines, enzymes, oxidative stress markers, and microbial metabolites-makes it a potential source of biomarkers reflecting neuroinflammatory pathways. This review discusses the biological rationale and emerging evidence supporting the use of GCF as a functionalized biofluid for early detection of dementia or asymptomatic neurodegeneration. By integrating advances in biosensing and lab-on-a-chip technologies, GCF analysis could become a minimally invasive, point-of-care approach to identify individuals at risk of neurodegenerative diseases. Exploring this oral-brain connection may open new perspectives in preventive medicine and personalized diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.